ACELYRIN, INC. Announces Suboptimal Outcomes in Izokibep Uveitis Trial and Market Performance In the ever-evolving sphere of pharmaceutical research, each clinical trial is a stepping stone to potential medical breakthroughs, albeit not without its share of setbacks. Recently, ACELYRIN, INC. a biopharmaceutical company at the forefront of immunological and inflammatory research, announced the topline results from its Phase 2b/3 study of izokibep in the treatment of uveitis, an inflammatory condition affecting the eye. Unfortunately, the trial did not meet its primary endpoint, nor did it achieve statistical significance in its secondary endpoints, posing a significant challenge to the company’s development...

Game-Changing Breakthrough in Thyroid Eye Disease Treatment: Lonigutamab Delivers Rapid Clinical Responses and Unparalleled Safety Profile

ACELYRIN, INC. has shared groundbreaking results from their Phase 1/2 proof-of-concept study, showcasing the remarkable efficacy and safety of their innovative subcutaneous anti-IGF-1R therapy, Lonigutamab, in treating Thyroid Eye Disease (TED). This remarkable achievement marks the first time a subcutaneous anti-IGF-1R therapy has demonstrated clinical responses in patients suffering from TED.Thyroid Eye Disease, also known as Graves ophthalmopathy, is a complex and debilitating autoimmune disorder affecting patients with Graves disease. The condition leads to inflammation and tissue expansion behind the eyes, resulting in proptosis (bulging eyes), diplopia (double vision), pain, and impaired vision. Conv...

SLRN's Stock Performance relative to it's Customers

SLRN's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
Acelyrin Inc	228.54	0.00	-268.52	202
SUBTOTAL	0.00	0.00	0.00	-

Sources: Acelyrin Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Acelyrin Inc’s corporate clients.
For your research, we’ve provided 9 tables on Acelyrin Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.